Piškur et al. analysed the cost effectiveness of the hormone medications anastrozole and tamoxifen for breast cancer.12 Obradović et al. analysed the cost effectiveness of determining the UGT1A1 genotype for irinotecan in monotherapy for colorectal cancer.13 The gene discussed is UGT1A1; the disease is breast cancer.